In September, hedge-fund manager and entrepreneur Martin Shkreli made headlines when he bought the rights to a 62-year-old drug, then raised the price from $13.50 a pill to $750.
And while more Americans are becoming keenly aware of this growing practice--price gouging on existing drugs--where's the outrage?
We typically believe in the free market, where innovation is rewarded, but some of the worst price gouging is occurring in the generic market on very old drugs.